Cost Reduction, Environmental Initiatives and Crisis Management through Large-Scale Capital Investment
First written in FY2016. 19 of 27 entries say "Advanced", first in FY2017-Q1. Latest entry: FY2026.
1 other company's latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「The Group made capital investments totaling ¥2,977 million, including investment in intangible fixed assets. Of this amount, ¥601 million was capital investment associated with the relocation of headquarters.」
Capital investment totaled ¥2,977 million and was allocated to production equipment in the Medical and Tape Businesses, as well as equipment associated with the relocation of headquarters. - FY2025-H1ReframedAnnual report
「To establish an optimal production system and reorganize the division of production across the Group, the Company decided during the interim consolidated accounting period to halt production on part of the coating equipment at the Saitama and Anjo Plants.」
The focus of the measures has shifted from expanding major capital investment to suspending equipment and shortening useful lives in connection with the establishment of an optimal production system and the reorganization of the division of production. - FY2024-Q3AdvancedAnnual report
「The building was completed in February 2023 and the manufacturing equipment in October 2023, and both are in full-scale operation.」
The major capital investment in adhesive-manufacturing equipment and buildings at the Saitama Plant was completed and transitioned to full-scale operation. The disclosed investment amount was ¥2,424 million, with an additional floor area of 1,907 m². - FY2024-Q2AdvancedAnnual report
「This was due to, among other factors, ¥2,244 million in payments for the acquisition of property, plant and equipment, including adhesive-manufacturing equipment and buildings at the Company's Saitama Plant. The adhesive-manufacturing equipment and buildings at the Saitama Plant were scheduled to commence operations in the second half of the fiscal year.」
Payments for the acquisition of adhesive-manufacturing equipment and buildings at the Saitama Plant totaled ¥2,244 million during the cumulative period to date, and the project had progressed to the stage where operations were scheduled to commence in the second half of the fiscal year. - FY2024-Q1AdvancedAnnual report
「Although the Company invested in adhesive-manufacturing equipment and buildings at its Saitama Plant, the investment amount was trending downward compared with the previous consolidated fiscal year. As depreciation expense exceeded investment, property, plant and equipment decreased by ¥209 million. The adhesive-manufacturing equipment and buildings at the Saitama Plant were scheduled to commence operations in the second half of the fiscal year.」
Investment in adhesive-manufacturing equipment and buildings at the Saitama Plant is continuing, while the investment amount is trending downward year on year. The equipment is scheduled to commence operations in the second half of the fiscal year. - FY2023-Q2AdvancedAnnual report
「The decrease in property, plant and equipment was mainly due to a ¥92 million decrease in property, plant and equipment from depreciation expense, despite an increase resulting from investment in adhesive-manufacturing equipment and buildings at the Company's Saitama Plant.」
Investment in adhesive-manufacturing equipment and buildings at the Saitama Plant is continuing. Payments for the acquisition of property, plant and equipment during the six-month period totaled ¥992 million. - FY2023-Q1AdvancedAnnual report
「The increase in property, plant and equipment was mainly due to an ¥86 million increase in property, plant and equipment resulting from investment in adhesive-manufacturing equipment and other assets at the Company's Saitama Plant, partly offset by depreciation expense.」
Investment in adhesive-manufacturing equipment and other assets at the Saitama Plant progressed, increasing property, plant and equipment by ¥86 million. Medical-device manufacturing equipment and construction of the new building were also completed. - FY2022AdvancedAnnual report
「The Group made capital investments totaling ¥3,981 million, including investment in intangible fixed assets.」
Total capital investment was ¥3,981 million, comprising ¥2,490 million for the Medical Business, ¥827 million for the Tape Business and ¥664 million for company-wide expenditures, including the renewal of core systems. - FY2022-Q3AdvancedAnnual report
「ニチバンメディカル First Plant Adhesive-tape manufacturing equipment and buildings 2,530 Internal funds November 2020 July 2022」
Investment in equipment and buildings at the Medical Business First Plant took concrete shape, with a planned investment of ¥2,530 million and full-scale operation of the manufacturing equipment scheduled for July 2022. The plan to transfer adhesive-manufacturing equipment and buildings to the Saitama Plant was also updated. - FY2022-Q2AdvancedAnnual report
「This was mainly due to ¥1,095 million in payments for the acquisition of property, plant and equipment associated with the construction of medical-device manufacturing equipment and buildings at ニチバンメディカル, among other factors.」
Payments for the acquisition of property, plant and equipment related to the construction of medical-device manufacturing equipment and buildings totaled ¥1,095 million, indicating progress in capital investment. - FY2022-Q1AdvancedAnnual report
「Current assets decreased by ¥22 million, while property, plant and equipment increased by ¥531 million. The increase in property, plant and equipment was mainly due to an increase in construction in progress resulting from investment by ニチバンメディカル in medical-device manufacturing equipment and other assets.」
Investment by ニチバンメディカル in medical-device manufacturing equipment and other assets increased property, plant and equipment and construction in progress, indicating progress in capital investment. - FY2021AdvancedAnnual report
「The Group made capital investments totaling ¥2,755 million, including investment in intangible fixed assets.」
Capital investment totaled ¥2,755 million, comprising ¥1,534 million for production equipment and other assets in the Medical Business, ¥587 million for the Tape Business and ¥632 million for the renewal of core systems. - FY2021-Q3AdvancedAnnual report
「Property, plant and equipment increased by ¥442 million. This increase was mainly due to an increase in construction in progress related to the construction of a new building at a subsidiary.」
While capital investment had contracted after construction of the major plant, construction in progress related to a new building at a subsidiary increased, resulting in a ¥442 million increase in property, plant and equipment. - FY2021-Q2SoftenedAnnual report
「Cash used in investing activities decreased by ¥209 million, or 19.2%, from the six-month period of the previous year to ¥882 million. This was mainly due to a decrease in payments for the acquisition of property, plant and equipment.」
Investing activities during the six-month period decreased 19.2% year on year to ¥882 million, and payments for the acquisition of property, plant and equipment also declined. The contraction in major capital investment has continued. - FY2020SoftenedAnnual report
「The Group made capital investments totaling ¥1,455 million, including investment in intangible fixed assets. Major investments included ¥630 million in the Medical Business, primarily for pharmaceutical and medical-hygiene-material manufacturing, cutting and packaging equipment, and ¥457 million in the Tape Business, primarily for adhesive-tape manufacturing, cutting and packaging equipment.」
Annual capital investment totaled ¥1,455 million, down from ¥2,054 million in the previous fiscal year. There was no disposal or sale of major facilities, and investment shifted from major projects centered on construction of the new plant to normal manufacturing equipment investment. - FY2020-Q3SoftenedAnnual report
「Cash used in investing activities decreased by ¥2,850 million, or 62.8%, from the nine-month period of the previous year to ¥1,685 million. This was mainly due to a decrease in payments for the acquisition of property, plant and equipment.」
Investing activities during the nine-month period decreased 62.8% year on year, and payments for the acquisition of property, plant and equipment also declined. Major capital investment centered on construction of the new plant is entering a contraction phase. - FY2019SoftenedAnnual report
「The Group made capital investments totaling ¥2,054 million, including investment in intangible fixed assets. Major investments included ¥681 million in the Medical Business, primarily for pharmaceutical production plants and research facilities, and ¥856 million in the Tape Business, primarily for adhesive-tape manufacturing, cutting and packaging equipment.」
With construction of the new plant largely completed, annual capital investment declined from ¥6,489 million in the previous fiscal year to ¥2,054 million. There were no plans for the construction or disposal of major facilities. - FY2019-Q3AdvancedAnnual report
「Cash used in investing activities increased by ¥959 million, or 26.8%, from the nine-month period of the previous year to ¥4,535 million. This was mainly due to an increase in payments for the acquisition of property, plant and equipment.」
Investing activities used ¥4,535 million during the nine-month period, and capital investment in property, plant and equipment continued. The increase in depreciation associated with the startup of the new plant was also cited as a factor behind the decline in operating income. - FY2019-Q2AdvancedAnnual report
「Cash used in investing activities increased by ¥2,835 million, or 356.8%, from the same period of the previous year to ¥3,630 million. This was mainly due to an increase in payments for the acquisition of property, plant and equipment.」
Investing activities used ¥3,630 million during the six-month period, including ¥3,605 million in payments for the acquisition of property, plant and equipment, indicating that capital investment is progressing. Depreciation also increased in connection with the startup of the new plant. - FY2019-Q1AdvancedAnnual report
「Operating income fell 23.4% year on year to ¥928 million. This reflected higher cost of sales in the Medical Business and a temporary increase in selling, general and administrative expenses, despite higher net sales, due in part to the startup of the new plant and production transfers.」
The new Anjo plant progressed from construction and completion to startup and production transfer, with the effects appearing in cost of sales and selling, general and administrative expenses. - FY2018AdvancedAnnual report
「The Group made capital investments totaling ¥6,489 million, including investment in intangible fixed assets. Major investments included ¥5,086 million in the Medical Business, primarily for the construction of a pharmaceutical production plant and research facilities, and ¥1,029 million in the Tape Business, primarily for adhesive-tape manufacturing, cutting and packaging equipment.」
Annual capital investment totaled ¥6,489 million, including ¥5,086 million in the Medical Business. The pharmaceutical production plants and research facilities were completed and commenced operations. - FY2018-Q3AdvancedAnnual report
「Payments for the acquisition of property, plant and equipment △ 3,434」
During the nine-month period ended the third quarter, payments for the acquisition of property, plant and equipment totaled ¥3,434 million, indicating that capital investment is continuing. - FY2017AdvancedAnnual report
「The Group made capital investments totaling ¥5,818 million, including investment in intangible fixed assets. Major investments included ¥4,653 million in the Medical Business, primarily for the construction of a pharmaceutical production plant and research facilities.」
Annual capital investment totaled ¥5,818 million, of which ¥4,653 million was invested in pharmaceutical production plants and research facilities in the Medical Business. - FY2017-Q3RestatedAnnual report
「However, profit in this field has increased as a result of promoting production efficiency and sales strategies.」
The company explains that continuing to improve production efficiency and pursue its sales strategy led to higher profit in the Industrial Products Field. - FY2017-Q2RestatedAnnual report
「However, profit in this field has increased as a result of promoting production efficiency and sales strategies.」
The company explains that continuing to improve production efficiency and pursue its sales strategy led to higher profit in the Industrial Products Field. - FY2017-Q1AdvancedAnnual report
「Operating income in the field increased as a result of the effects of production equipment investment aimed at improving profitability, together with the results of product and sales strategies.」
The company states that the profitability improvements from investment in production equipment, together with its product and sales strategies, contributed to higher operating income. - FY2016First statedAnnual report
「2) Launch of major capital investment *Updating production methods with the aim of reducing costs, addressing environmental requirements in production and managing risks」
The purposes of capital investment are explained from 3 perspectives: costs, environmental measures in production and risk management.